Endovascular Treatment of Ischemic Heart Disease in Oncohematological Patients

Improvement of the treatment setting for oncohematological diseases allowed to improve the treatment results, to increase the life expectancy, to change life quality. This is one of the factors explaining the tendency of the increase in the incidence of coronary heart disease with oncological disease combination.

Study includes the treatment results of 27 patients (20 men and 7 women) underwent coronary arteries stenting before the treatment of the main oncohematological disease.

The average age of the patients was 64 ± 11.63 years. The distribution of the patients according to the main diagnosis was: 8 (33.3%) - diffuse large B-cell lymphoma, 1 (3.7%) - extranodal B-cell lymphoma from marginal MALT-type cells, 5 (18, 5%) - follicular lymphoma, 1 (3.7%) - acute lymphoblastic leukemia, 6 (22.2%) - multiple myeloma, 2 (7.4%) - T-cell anaplastic lymphoma, 2 (7.4%) - primary myelofibrosis, 1 (3.7%) - non-Hodgkin`s lymphoma, unspecified type.

All patients underwent examination: general and special exams, laboratory diagnostics. All patients underwent percutaneous coronary intervention. Complete myocardium revascularization was performed in 12 (44.4%) patients, incomplete revascularization was due to chronic occlusive lesions of coronary arteries in 5 (30%) cases, small diameter of arteries in 4 (26.6%), lesion of distal coronary arteries in 4 (26.6%).

Good long-term results after revascularization were obtained in our study. There were no mortality cases due to coronary artery disease. Mortality was due to the progression of the main oncohematological disease in the early and long-term periods after revascularization.